PCG Digital

Recent News

  • As Investors Pile into Responsible Funds, Ethical Tech Company Bubblr Positions for Positive Impact on the Online Economy

    New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Steven Saunders proclaims the internet is broken. Not because he can't login to his Wi-Fi, but because he sees deep-rooted injustice, something he has fought his entire career. As CEO of ethical tech company Bubblr, Inc., Saunders is at the helm of a newly public innovative powerhouse with a mission to change the system. Why? Because Bubblr believes the current model is broken: It is an...

    2021-02-23 8:30 AM ET
  • Soligenix is Ready for Commercialization of SGX301 (HyBryte(TM)); FDA Has Approval Process on Fast Track

    New York, New York--(Newsfile Corp. - February 23, 2021) - PCG Digital -- Operational efficiency and sound financial management lead to positive results. That statement sums up why Soligenix (NASDAQ: SNGX) is fast approaching a new drug application (NDA) submission and potential FDA approval for SGX301 (synthetic hypericin), a photodynamic treatment option to battle the debilitating effects of cutaneous T-Cell lymphoma (CTCL).The most recent treatment option in their rare disease pipeline, SGX301, will potentially be known as HyBryte™ following...

    2021-02-23 8:30 AM ET
  • U.S. Patent Follows Key Advisory Board Additions-What's Next for Bubblr?

    New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - 2021 has already been a big year for ethical technology company Bubblr (OTC Pink: BBLR). After going public and expanding its advisory board with notable industry experts in late 2020, Bubblr received a Notice of Allowance from the U.S. Patent and Trademark Office for a utility patent application for its Internet-based Search Mechanism. This patent will help users interact and search anonymously with providers of goods...

    2021-02-09 8:30 AM ET
  • Soligenix's Upcoming Catalysts Highlight Growth Potential as it Sheds Light on its Commercialization of SGX301

    New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital: Soligenix (NASDAQ: SNGX) continues to build excitement for its SGX301 candidate following strong Phase 3 data and commercialization plans. The company recently held an investor webcast to further explain the company's plans for commercializing its ground-breaking SGX301 candidate for the treatment of cutaneous T-cell lymphoma (CTCL). Here are some key takeaways from the commercialization Q&A: 1. Soligenix will commercialize SGX301 in the U.S. on its ownDuring the presentation,...

    2021-02-09 8:30 AM ET
  • Lexaria Outlook is Promising After Jazz Acquisition of GW

    New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabinoids as a mainstream medical solution. This week, his dream is coming true. Jazz Pharmaceuticals, a major player with $2.3 billion in annual revenue, has entered the fray.The deal went down on Wednesday, February 3rd. Jazz completed an acquisition of GW Pharmaceuticals, developers of Epidiolex, the first...

    2021-02-09 8:30 AM ET
  • Soligenix Poised to Announce US Commercialization Plans of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma

    New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy. Researching and developing new treatments for unmet medical needs has become increasingly important as the world continues to battle through the worst pandemic in our lifetime. While the news and focus of health innovation continues to be largely on COVID-19, medical breakthroughs continue to progress across the board.Soligenix, Inc. (NASDAQ: SNGX) is one such biopharmaceutical company...

    2021-01-25 8:30 AM ET
  • Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and Pfizer

    New York, New York--(Newsfile Corp. - December 9, 2020) -  The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 million people globally have died from the coronavirus, including over 274,000 deaths in the United States. At the same time, millions of people have lost their jobs, businesses, and other income sources. The only way to truly recover from this pandemic is from widespread vaccination and continued...

    2020-12-09 8:30 AM ET
  • Pfizer and Moderna COVID-19 Vaccine Candidates Are Promising, but Soligenix's Civax (TM) May Be a Better Alternative

    New York, New York--(Newsfile Corp. - November 17, 2020) - Enthusiasm is surrounding Pfizer's and Moderna's announcement of COVID-19 vaccine candidates that may soon become ripe for approval. But, in all fairness to the progress, tempering some of the excitement is warranted. There are two significant concerns. First, both Pfizer and Moderna candidates use synthetic mRNA technology to activate the immune system against the virus and must be kept at minus 70 degrees Celsius (-94 F) or below,...

    2020-11-17 8:00 AM ET